Brief: ABL Bio Inc Applies For 1st Phase Clinical Trials For Parkinson's Disease Treatment To U.S. FDA
04/10/2022 01:57
Oct 4 (Reuters) - ABL Bio Inc 298380.KQ :
* APPLIES FOR 1ST PHASE CLINICAL TRIALS FOR PARKINSON'S
DISEASE
TREATMENT TO U.S. FDA
Further company coverage: 298380.KQ
(Reporting by Joyce Lee)
((JungYoon.Lee@thomsonreuters.com;))
Recent news on ABL Bio
See all newsBrief: Abl Bio Inc - Raises 37.7 Billion Won Worth Of New Shares
Brief: Abl Bio Announces Grabody-B Brain Delivery Platform License Agreement With GSK To Develop Novel Medicines For Neurodegenerative Diseases
Brief: Abl Bio Inc Signs Agreement With Intocell Inc To Use Its Antibody-Drug Conjugate Tech In Product Development
Brief: I-Mab And Abl Bio Announce Latest Updates Of Pd-L1 And 4-1BB Bispecific Antibody TJ-L14B/ABL503
Brief: Abl Bio To Acquire Real Estate Worth 65 Billion Won